DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2025 Conference
Aptorum Group Limited - Class A Ordinary Shares (APM)
Company Research
Source: GlobeNewswire
NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, announce two poster presentations at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, taking place December 1-4, 2025, in San Diego, CA, and online. The presentations will highlight the potential of brain-enriched and inflammation-associated microRNAs as epigenetic biomarkers of neurodegeneration. Details of the presentations include: Session. Clinical trials: Biomarkers, including plasma Date/Time. Wednesday, December 3rd, 2025; 7:15 A.M. – 5:30 P.M. PST Venue. Hilton San Diego Bayfront, San Diego, CA Poster #225: Developing microRNA classifiers enriched in brain and associated with inflamma
Show less
Read more
Impact Snapshot
Event Time:
APM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
APM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
APM alerts
High impacting Aptorum Group Limited - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
APM
News
- Aptorum Group (NASDAQ:APM) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 Conference [Yahoo! Finance]Yahoo! Finance
- Aptorum Group Limited Announces Up To $6 Million Registered Direct Offering [Yahoo! Finance]Yahoo! Finance
- Aptorum Group Limited Announces Up To $6 Million Registered Direct OfferingGlobeNewswire
- As part of the planned merger with DiamiR Biosciences, Aptorum Group will expand its board and management team with seasoned executivesGlobeNewswire
APM
Sec Filings
- 12/4/25 - Form EFFECT
- 11/18/25 - Form DEL
- 11/17/25 - Form F-1
- APM's page on the SEC website